Analysts’ Views On Concert Pharmaceuticals Inc. (CNCE)

0
67
REV
REV

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) finished Friday with an addition of $0.43 to close at $5.84, an upside of 7.95 percent. An average of 348,940 shares of common stock have been traded in the last five days. There was a gain of $0.88 in the past week, and it reached a new high 19 times over the past 12 months. The last 20 days have seen an average of 342,325 shares traded, while the 50-day average volume stands at 407,312.

CNCE stock has increased by 21.16% in the last month. The company shares reached their 1-month lowest point of $4.20 on 12/07/22. With the stock rallying to its 52-week high on 08/11/22, shares of the company touched a low of $2.57 and a high of $7.37 in 52 weeks. It has reached a new high 18 times so far this year and achieved 85.40% or $2.69 in price. In spite of this, the price is down -20.76% from the 52-week high.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored


Insider Transactions

CNCE stock investors should be aware that Concert Pharmaceuticals Inc. (CNCE) stock had its last reported insider trading activity 78 days ago on Oct 14. In this transaction, the insider spent $21,553. Chief Executive Officer, Tung Roger D, disposed of 13,480 shares at a price of $3.09 on Feb 15. The insider now owns more than $41,653 worth of shares. Prior to that, Chief Operating Officer Stuart Nancy went on to Sale 6,049 shares at $3.08 each on Feb 14. An amount of $18,631 was transacted.

Valuation Metrics

Concert Pharmaceuticals Inc. (CNCE) stock’s beta is 0.37. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 8.90, the price-to-book (PB) ratio at 2.18.

Financial Health

The quick ratio of Concert Pharmaceuticals Inc. for the three months ended September 29 was 9.00, and the current ratio was 9.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending September 29. Its gross profit as reported stood at $110.09 million compared to revenue of $32.58 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Concert Pharmaceuticals Inc.’s return on assets was -79.90%.

Earnings Surprise

For the three-month period that ended September 29, Concert Pharmaceuticals Inc. had $0.68 million in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$28.9 million in the quarter, while revenues were grew 7.68%. The analyst consensus anticipated Concert Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.59 per share, but it turned out to be -$0.58, a 1.70% surprise. For the quarter, EBITDA amounted to -$29.53 million. Shareholders own equity worth $47.94 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Concert Pharmaceuticals Inc. (CNCE) price momentum. RSI 9-day as of the close on 30 December was 76.80%, suggesting the stock is Overbought, with historical volatility in this time frame at 76.42%.

As of today, CNCE’s price is $5.15 +17.74% or $0.88 from its 5-day moving average. CNCE is currently trading +18.46% higher than its 20-day SMA and -15.12% lower than its 100-day SMA. However, the stock’s current price level is -1.35% below the SMA50 and +98.64% above the SMA200.

The stochastic %K and %D were 87.91% and 82.60%, respectively, and the average true range (ATR) was 0.37. With the 14-day stochastic at 96.30% and the average true range at 0.35, the RSI (14) stands at 68.49%. The stock has reached 0.42 on the 9-day MACD Oscillator while the 14-day reading was at 0.51.

Analyst Ratings

Berenberg launched coverage on Concert Pharmaceuticals Inc. (NASDAQ: CNCE) in its analyst report released on December 16, 2020. The firm assigned the stock a Buy rating.

LEAVE A REPLY

Please enter your comment!
Please enter your name here